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Cervical cancer is caused by human papillomavirus (HPV) in 
collaboration with other non-viral factors. The uterine cervix is 
hormone responsive and female hormones have been implicated 
in the pathogenesis of the disease. HPV transgenic mice express-
ing HPV16 oncogenes E6 (K14E6) and/or E7 (K14E7) have been 
employed to study a mechanism of estrogen and estrogen receptor 
α (ERα) in cervical carcinogenesis. A chronic exposure to physi-
ological levels of exogenous estrogen leads to cervical cancer in 
the HPV transgenic mice, which depends on ERα. The receptor 
is composed of multiple functional domains including a DNA-
binding domain (DBD), which mediates its binding to estrogen-
responsive elements (EREs) on target genes. A  transcriptional 
control of genes by ERα is mediated by either DBD-dependent 
(classical) or DBD-independent (non-classical) pathway. Although 
molecular mechanisms of ERα in cancer have been characterized 
extensively, studies investigating importance of each pathway for 
carcinogenesis are scarce. In this study, we employ knock-in mice 
expressing an ERα DBD mutant (E207A/G208A) that is defec-
tive specifically for ERE binding. We demonstrate that the ERα 
DBD mutant fails to support estrogen-induced epithelial cell pro-
liferation and carcinogenesis in the cervix of K14E7 transgenic 
mice. We also demonstrate that cervical diseases are absent in 
K14E7 mice when one ERα DBD mutant allele and one wild-type 
allele are present. We conclude that the ERα classical pathway is 
required for cervical carcinogenesis in a mouse model.
Introduction
Although cervical cancer incidence has been decreasing in devel-
oped countries, the disease remains the second most prevalent malig-
nancy and the second leading cause of death by cancer in women 
in developing countries (1). Most cervical malignancies arise in pre-
menopausal women and are associated with high-risk human papillo-
mavirus (HPV) (2). Regular Pap test and HPV vaccines are effective 
in preventing the cancer (3) but not readily available to women in 
developing countries or low-income population. In addition, the cur-
rent therapies for cervical cancer (i.e. surgery, chemotherapy and 
radiation) are not effective in treating late stage or recurrent diseases 
(4). Precancer lesions [i.e. cervical intraepithelial neoplasia (CIN)] 
detected by Pap test can be easily removed by simple surgical proce-
dures, thereby preventing the cancer. These surgeries, however, are 
associated with adverse outcomes in future pregnancy, including pre-
term birth and infant morbidity (5). A better understanding of cervical 
cancer pathogenesis is needed to develop a non-invasive method to 
manage the cancer and CIN more effectively.
A subset of >100 HPV types is causally associated with various 
human cancers including those in the uterine cervix (2). They are 
called high-risk HPVs and transmitted mainly by sexual contacts. 
Most commonly found in cancers is HPV16 followed by HPV18, 
both of which are commonly targeted by current prophylactic HPV 
vaccines (3). These two types account only for 70–80% of all cervical 
cancers and thus those vaccines have little impact on the remainder. 
High-risk HPVs code for E6 and E7 oncogenes and numerous stud-
ies have proved their potent oncogenic activities in vitro and in vivo 
(2,6). The tumorigenic potential of these viral oncoproteins depends 
on their ability to interact with various cellular proteins regulating 
cancer-associated cellular processes such as apoptosis and cell cycle 
(2). Most notably, E6 promotes degradation of a key apoptosis regula-
tor p53 and E7 inactivates a cell cycle regulator pRb. E6 and E7 are 
required not only for the development of cervical cancer but also for 
its continued growth (7–9). Evidence also suggests that HPV is not 
sufficient to cause cervical cancer and other HPV-associated malig-
nancies (6,10).
Several lines of epidemiological evidence implicate female hor-
mones (e.g. estrogen) in HPV-associated cervical cancer (10,11). 
Consistently, estrogen is required for cervical cancer to develop in 
HPV transgenic mice (12,13). Cervical disease occurring in those 
mice is progressive and preferentially arises in the transformation 
zone, which mimics human cervical cancer (12). It also shows the 
expression pattern of biomarkers similar to that of the human cancer 
(14). Estrogen receptor α (ERα) is necessary for the development and 
continued growth of cervical cancer in the same mouse model but not 
for HPV oncogene functions (15,16). ERα is also crucial for estrogen-
induced cell proliferation in the normal cervical epithelium (16).
ERα is a transcription factor and composed of multiple functional 
domains, activation function 1 domain, DNA-binding domain (DBD) 
and ligand-binding domain encompassing activation function 2 domain. 
In the classical pathway, the DBD is responsible for direct binding 
of ERα to estrogen-responsive elements (EREs) on its target genes, 
thereby regulating their transcription (17). In non-classical or tethering 
pathway, ERα indirectly binds DNA through interactions with other 
transcription factors such as AP1 and Sp1. Physiological importance 
of the ERα classical pathway in estrogen-responsive tissues such as 
uterus and bone has been demonstrated by studies using a knock-in 
mouse model, which expresses an ERα DBD mutant (E207A/G208A) 
defective for binding EREs (i.e. deficient for the classical pathway) 
(18–20). Using the same knock-in mice, we here report that the ERα 
DBD is required for estrogen-dependent cervical carcinogenesis in the 
K14E7 transgenic mouse model. Our results support that the ERα clas-
sical pathway is crucial for estrogen-dependent cervical cancer in vivo.
Materials and methods
Mice and treatments
Mice used in this study were described previously (18,21–24) and summa-
rized in Supplementary Table SI, available at Carcinogenesis Online. All 
mice were genotyped by PCR. Some mice were ovariectomized at the age 
of 6–8 weeks and recovered for 2 weeks. They were then intraperitoneally 
injected with ethanol vehicle or 17β-estradiol (E2; 1  μg) for 7  days. For 
longer E2 treatments, slow-releasing E2 tablets (0.05 mg/60 days) (Innovative 
Research of America, Sarasota, FL) were subcutaneously inserted under the 
dorsal skin every 2 months as described previously (25). Subsets of mice 
were intraperitoneally injected with bromo-deoxyuridine (BrdU) (3.75 mg 
Abbreviations: ASM, atypical squamous metaplasia; BrdU, bromo-deoxyur-
idine; CIN, cervical intraepithelial neoplasia; DBD, DNA-binding domain; E2, 
17β-estradiol; ERα, estrogen receptor α; ERE, estrogen-responsive element; 
FGF, fibroblast growth factor; HPV, human papillomavirus; IGF1, insulin-
like growth factor 1; NTG, non-transgenic; PR, progesterone receptor; wt, 
wild-type.
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per mouse) 1 h prior to killing to measure cell proliferation. All procedures 
were carried out according to animal protocols approved by the University of 
Houston Institutional Animal Care and Use Committee and the University of 
Wisconsin School of Medicine and Public Health Institutional Animal Care 
and Use Committee.
Tissue processing and histology
The female reproductive tracts were harvested, fixed in 4% paraform-
aldehyde and embedded in paraffin. The tissues were serially sectioned 
throughout cervices at 5 μm thickness. Every 10th slide was stained with 
hematoxylin and eosin and the worst disease was determined as described 
previously (13,14).
Immunohistochemistry
Antibodies were purchased from Santa Cruz Biotechnology [ERα (H184), 
progesterone receptor (PR) (H190) and p16], Calbiochem (BrdU), Neomarkers 
(MCM7), Thermo Scientific (Ki67) and Rockland Immunochemicals (bioti-
nylated anti-rabbit/mouse IgG). For Ki67 immunohistochemistry, sections 
were sequentially incubated with anti-Ki67 antibody (1:200 in 5% goat serum 
in phosphate-buffered saline) and biotinylated anti-rabbit IgG, and then with 
ABC complex (Vector Laboratories) according to the manufacturer’s instruc-
tions. The immune complex was visualized by an incubation in 3,3′-diam-
inobenzidine (Sigma) dissolved in phosphate-buffered saline (0.5 mg/ml). 
Immunohistochemistry for MCM7, PR, p16, ERα and BrdU was performed 
as described previously (14,26,27).
Statistical analyses
One-sided Fisher’s exact test and Wilcoxon rank-sum test were carried out 
with MSTAT software version 5.5, which may be downloaded at www.mcar-
dle.wisc.edu/mstat. Fisher’s exact test was used for cancer incidence, and 
Wilcoxon rank-sum test for disease severity and percentage of Ki67+/BrdU+ 
cells.
Results
A functional ERα DBD is required for E2-induced cell proliferation in 
the cervical epithelium
Epithelial cell proliferation in the mouse cervix depends on estrogen 
(E2) and ERα (16). To determine whether the ERα classical path-
way is crucial for cervical epithelial cell proliferation, we employed 
the non-classical ER knock-in (NERKI) mice expressing the DBD 
mutant (E207A/G208A) (18). This mutant allele will be referred to as 
NERKI or N herein. Ovariectomized mice were treated with vehicle or 
E2, and cervical tissues were histologically evaluated and analyzed for 
BrdU incorporation to measure cells undergoing DNA synthesis. The 
epithelia of cervical tissues from vehicle-treated ERα+/− and ERαN/− 
mice were similarly hypoplastic (Figure  1A). The treatment with 
E2 resulted in physiologic hyperplasia in the cervical epithelium of 
ERα+/− but not ERαN/− mice (Figure 1A). Consistently, compared with 
vehicle control, number of BrdU-positive cervical epithelial cells was 
significantly increased upon E2 treatment in ERα
+/− but not in ERαN/− 
mice (Figure 1B and C). We observed similar results in the vaginal 
epithelium (Figure 1D and E). ERα expression was predominant in 
the nuclei of cervical stromal and epithelial cells regardless of E2 
treatment, which was similar in ERα+/− and ERαN/− mice (Figure 1F). 
These results demonstrate that the classical pathway of ERα (i.e. ERE 
binding) is required for E2-induced epithelial cell proliferation and 
thickening of epithelia in the lower reproductive tract of female mice.
A functional ERα DBD is required for early stage of cervical  
carcinogenesis in K14E7 mice
The phenotypes in ERαN/− mice described above were reminiscent 
of those observed in ERα−/− mice (16). We therefore hypothesized 
Fig. 1. Female lower reproductive tracts of ERαN/− mice lack physiologic responses to E2. (A) ERα DBD mutant fails to support E2-induced hyperplasia in the 
cervical epithelia. Ovariectomized mice of indicated genotype were treated with ethanol vehicle (Veh) or E2 for 7 days. Representative images of hematoxylin 
and eosin (H&E)-stained cervical sections are shown. Scale bar, 50 μm. (B) ERα DBD mutant fails to support E2-induced cell proliferation in the cervical 
epithelia. Cervical sections shown in A are analyzed by BrdU immunohistochemistry (IHC) and representative images are shown. Black lines separate epithelia 
from stroma. Scale bar, 10 μm. (C) Results shown in B are quantified and shown as mean ± standard error of the mean. Group size (n) is indicated. *P = 0.05, 
**P = 0.01. (D and E) ERα DBD mutant does not support physiologic responses to E2 in the vaginal epithelia. Vaginal tissue sections from mice described in 
A were stained with H&E (D) or for BrdU (E). Scale bars, 25 μm. (F) ERα expression in ERαN/− is similar to ERα+/− cervix. Cervical sections were stained for 
ERα and nuclei were counterstained with hematoxylin. Scale bar, 25 μm.
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that cervical neoplasia would not arise in K14E7/ERαN/− mice simi-
lar to K14E7/ERα−/− mice (16). To test this hypothesis, we gener-
ated K14E7/ERαN/− and K14E7/ERα+/− mice and treated them for 
6 months with E2. Three of 10 (30%) K14E7/ERα
+/− mice had cervi-
cal cancer and the remainder had high-grade dysplasia, CIN2 or CIN3 
(Table I). Cervical disease burden in this genotype was comparable 
with that in K14E7/ERα+/+ mice on a mixed genetic background (25), 
indicating that ERα is haplosufficient for cervical carcinogenesis. In 
contrast, none of 12 K14E7/ERαN/− mice had cervical cancer or CIN 
(Table I). Although difference in cancer incidence did not reach sta-
tistical significance (P = 0.08), overall cervical disease severity was 
significantly worse in K14E7/ERα+/− mice compared with K14E7/
ERαN/− mice (P = 6.91 × 10−6). It was also evident that the cervical 
epithelia of K14E7/ERαN/− mice were hypoplastic as opposed to the 
hyperplastic epithelia in K14E7/ER+/− control mice (Figure  2A). 
Consistently, a fraction of Ki67-positive cells (i.e. proliferating cells) 
was dramatically diminished in K14E7/ERαN/− mice compared with 
K14E7/ERα+/− control mice (Figure 2B and C). Atypical squamous 
metaplasia (ASM) in the cervical transformation zone is believed to 
be the first step in cervical carcinogenesis and ERα is required for its 
development (16). We therefore investigated whether K14E7/ERαN/− 
mice lacked ASM. Identical to K14E7/ERα−/− mice (16), ASM was 
absent in all K14E7/ERαN/− mice, whereas it was present in all K14E7/
ERα+/− control mice (Figure 2D). K14E7/ERα+/+ mice are also sus-
ceptible to vaginal neoplasia upon E2 treatment (13,16). Although all 
K14E7/ERα+/− control mice had varying severity of vaginal neoplastic 
disease including cancer, none of the K14E7/ERαN/− mice displayed 
such disease (Table I). These results indicate that the ERα classical 
pathway (i.e. ERα DBD function) is necessary for initiation of cervi-
cal/vaginal neoplasia in K14E7 transgenic mice.
HPV16 E7 and the ERα classical pathway are functional in K14E7/
ERαN/f mice treated with E2 for 4 weeks
We next sought to determine whether the ERα classical pathway is dis-
pensable for progression and/or persistence of cervical diseases. We 
reasoned that it could be addressed using CMVCreER/K14E7/ERαN/f 
mice, which allow temporal deletion of floxed ERα allele [expressing 
wild-type (wt) ERα] after the disease is developed. The ERα mutant 
(E207A/G208A) does not interfere with ERE binding of wt ERα in an 
in vitro reporter assay (18). To verify this in the mouse cervix, we gen-
erated non-transgenic (NTG)/ERα+/f, NTG/ERαN/f, K14E7/ERα+/f and 
K14E7/ERαN/f mice and treated them for 4 weeks with same dose of 
E2 used in the cancer study shown in Table I. Cervical tissue sections 
were evaluated for BrdU incorporation. Basal and suprabasal cell pro-
liferations in the cervical epithelia of NTG/ERα+/f and NTG/ERαN/f 
were not significantly different (Figure 3A and B), indicating that the 
classical pathway of wt ERα was not inhibited in those heterozygotic 
mice. Induction of suprabasal cell proliferation is one of the hallmarks 
for E7 function in the squamous epithelium (25). Suprabasal cell pro-
liferation was dramatically increased in K14E7/ERα+/f mice com-
pared with NTG/ERα+/f mice (2.3 ± 0.5 versus 0.4 ± 0.3%, P = 0.02); it 
was similarly increased in K14E7/ERαN/f mice compared with NTG/
ERαN/f mice (1.3 ± 0.2 versus 0.4 ± 0.1%, P = 0.02) (Figure 3A and B). 
Suprabasal cell proliferation in K14E7/ERαN/f mice was not different 
from that in K14E7/ERα+/f mice (P  =  0.14). These results indicate 
that E7 is functional on ERαN/f background. Basal cell proliferation 
in K14E7/ERα+/f and K14E7/ERαN/f mice was similar to that in NTG/
ERα+/f and NTG/ERαN/f mice (P = 0.22), which further supports that 
the ERα classical pathway is functional in ERαN/f mice.
Cervical disease is absent in K14E7/ERαN/f mice
To determine if the ERα classical pathway is also crucial for later 
stages of cervical carcinogenesis, we generated four genotypes of 
mice: K14E7/ERαN/f, K14E7/ERα+/f, CMVCreER/K14E7/ERαN/f and 
CMVCreER/K14E7/ERα+/f. We treated them with E2 for 6  months 
and anticipated that all genotypes would similarly develop cervical 
diseases based on results shown in Figure 3 as well as previously pub-
lished results (26). If it were the case, we were to temporally acti-
vate CreER fusion protein by tamoxifen to delete floxed ERα allele 
(f), continue E2 treatment for additional months and compare disease 
severity in CMVCreER/K14E7/ERαN/f and CMVCreER/K14E7/ERα+/f 
mice at the endpoint. Surprisingly, however, cervical disease was 
absent on ERαN/f background after 6-month E2 treatment (Table I, see 
K14E7/ERαN/f). In contrast, 6 of 37 (16.2%) K14E7/ERα+/f control 
mice developed invasive cancer and the remainder had CIN2 or CIN3 
(Table I). Both cancer incidence (P = 0.05) and overall disease sever-
ity (P = 1.09 × 10−11) were significantly greater in K14E7/ERα+/f mice 
compared with K14E7/ERαN/f mice. In addition, the cervical epithelia 
of K14E7/ERαN/f mice were hypoplastic, whereas those of K14E7/
ERα+/f mice were hyperplastic (Supplementary Figure S1, available 
at Carcinogenesis Online). Consequently, we were unable to evalu-
ate whether the ERα classical pathway is required for later stages 
of cervical carcinogenesis. It should be mentioned that genotypes 
were pooled based on ERα status regardless of CMVCreER status 
because CMVCreER transgene did not affect disease severity in this 
study (data not shown) similarly to previously published results (26) 
and none of the mice were treated with tamoxifen. Cervical cancer 
incidence in K14E7/ERα+/f mice was similar to K14E7/ERα+/− mice 
(P  =  0.29), confirming haplosufficiency of ERα. Vaginal diseases 
were also absent in K14E7/ERαN/f mice, which was significantly dif-
ferent from K14E7/ERα+/f mice (P = 2.28 × 10−10; Table I).
Long-term but not short-term E2 treatment results in defects in  
cervical epithelial cell proliferation in K14E7/ERαN/f mice
We compared cervical epithelial cell proliferation in K14E7/ERαN/f 
and K14E7/ERα+/f mice treated for 6 months with E2. Both basal and 
suprabasal cell proliferations were significantly reduced in K14E7/
ERαN/f mice compared with K14E7/ERα+/f control mice (Figure 4A 
and B). This was surprising because we did not observe such defects 
in the same mice treated with E2 for 4 weeks (see Figure 3). Ages of 
mice at the endpoints were 2.5 months for those treated for 4 weeks in 
Figure 3 and 7.5 months for those treated for 6 months. To determine 
Table I. Summary of lower reproductive tract disease statesa  
Genotypes Group size, n No disease Dysplasia only Cancer and dysplasia Cancer incidence, %
Cervix (vagina) CIN1 (VIN1) CIN2 (VIN2) CIN3 (VIN3) Cervix (vagina) Cervix (vagina)
K14E7/ERα+/− 10 0 (0) 0 (2) 4 (3) 3 (3) 3 (2) 30 (20)
K14E7/ERαN/− 12 12 (12) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
bK14E7/ERα+/f 37 0 (3) 0 (16) 13 (16) 18 (1) 6 (1) 16.2 (2.7)
cK14E7/ERαN/f 22 22 (22) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
VIN, vaginal intraepithelial neoplasia.
aMice were scored histopathologically for the worst disease present in the cervix or, in parentheses, the vagina of each mouse.
bK14E7/ERα+/f (n = 20) and CMVCreER/K14E7/ERα+/f (n = 17) were pooled; the two genotypes showed similar neoplastic diseases (data not shown). No mice 
were treated with tamoxifen.
cK14E7/ERαN/f (n = 11) and CMVCreER/K14E7/ERαN/f (n = 11) were pooled; the two genotypes showed similar neoplastic diseases (data not shown). No mice 
were treated with tamoxifen.
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if the difference in phenotypes was due to age of mice, we generated 
NTG/ERα+/f, NTG/ERαN/f, K14E7/ERα+/f and K14E7/ERαN/f mice and 
treated them for 4 weeks with E2 at 6.5 months of age (7.5-month-
old at killing). Basal cell proliferation was similar in all genotypes 
(Figure  4C and D). Suprabasal cell proliferation was significantly 
increased in K14E7/ERα+/f and K14E7/ERαN/f mice compared with 
NTG/ERα+/f and NTG/ERαN/f mice, respectively (Figure 4C and D). 
These results were similar to those shown in Figure 3, indicating that 
K14E7/ERαN/f mice respond similarly to 4-week long E2 treatment 
regardless of their age. Basal and suprabasal cell proliferations were 
significantly decreased in K14E7/ERαN/f mice treated for 6  months 
compared with age-matched mice treated for 4 weeks (P  <  0.05) 
(Figure 4B and D). We conclude that K14E7/ERαN/f mice have altered 
response to long-term (e.g. 6 months) treatment with E2.
HPV oncogenes and ERα classical pathway are active in cervices 
of K14E7/ERαN/f mice treated with E2 for 6 months
One possibility for the lack of cervical disease in K14E7/ERαN/f 
mice was that a function of E7 was inhibited. We, however, found 
that MCM7 and p16, surrogate markers for E7 function (28), were 
highly expressed in the cervical epithelium of K14E7/ERαN/f mice 
similar to K14E7/ERα+/f control mice (Figure 5A). These results are 
consistent with the fact that E7 expression and MCM7 upregulation 
are independent of ERα status (16). Another possibility was that the 
mutant ERα blocked ERE binding of wt ERα when treated with E2 
for 6 months but not for 4 weeks (see Figure 3). We used PR as a 
marker for ERα classical pathway because PR was not expressed in 
ERαN/− cervix treated with E2 (Supplementary Figure S2, available 
at Carcinogenesis Online). PR expression was evident in cervical 
epithelia and stroma of all K14E7/ERα+/f control mice and 10 out of 
13 K14E7/ERαN/f mice (Figure  5B). Interestingly, 3 of 13 cervical 
tissues showed strong PR staining in the stroma but not in the epi-
thelia (Figure 5B). Subcellular localization of ERα was not altered 
in K14E7/ERαN/f cervices; the majority of ERα was present in the 
nucleus regardless of ERα genotype (Figure 5B). These results indi-
cate that the ERα mutant did not grossly inhibit wt ERα in K14E7/
ERαN/f cervices when treated for 6 months with E2.
Discussion
Molecular mechanisms by which ERα promotes estrogen-dependent 
cancers such as breast cancer have been extensively studied. Although 
many studies have focused on how ERα binds to DNA and how 
coregulators modulate transcription of ERα target genes (29), only 
few studies have evaluated whether ERE binding is crucial for growth 
of breast cancer cells (30,31). Our present study demonstrated that 
K14E7/ERαN/− mice were resistant to the development of ASM, the 
earliest stage of cervical neoplasia (Figure 2D), indicating that the 
ERα classical pathway is necessary for initiation of cervical cancer. 
We speculate that ERE binding may be also crucial for progression 
and/or persistence of cervical cancer because the ERα classical path-
way is associated with proliferation of breast cancer cells (30,31).
Potential ERα target genes that are crucial for cervical carcinogen-
esis and regulated by the classical pathway
A plethora of genes are either upregulated or downregulated by ERα, 
many of which are involved in regulation of cell cycle, apoptosis 
and migration (32). ERα expression inhibits the invasive potential of 
human cervical cancer cells in vitro (33). ERα is often lost in human 
cervical cancer but expressed in surrounding stroma (34). Deletion of 
stromal ERα ablates cervical neoplasia in the K14E7 transgenic mice 
(26). These observations put forth the hypothesis that stromal ERα 
promotes but epithelial ERα suppresses cervical cancer. It is conceiv-
able that ERα-dependent paracrine factor(s) secreted by stromal cells 
may promote cervical carcinogenesis. If these were correct, regulation 
of paracrine factors by ERα is likely independent of HPV oncogenes 
because cervical stromal cells do not express them in these mice (13). 
Estrogen upregulates genes coding for such factors including insulin-
like growth factor 1 (IGF1), fibroblast growth factors (FGFs) and Wnt 
ligands. Transcriptional regulation of Igf1 by estrogen requires direct 
binding of ERα to EREs (35). IGF1 promotes proliferation of cervical 
cancer cells and IGF1 receptor is required for their growth in soft agar 
(36). Fgf2 and Fgf9 are upregulated by estrogen and contain consen-
sus EREs upstream of transcription start site (37). Fgf10 also contains 
an ERE, of which location and sequence are conserved in human and 
mouse (37). Activation of FGFR2 IIIb (receptor for FGF10) or FGFR2 
IIIc (receptor for FGF2 and FGF9) promotes proliferation of human 
cervical cancer cells (38,39). Genes coding for several Wnt ligands 
(e.g. WNT1, WNT2B, WNT4, WNT10B) also contain consensus EREs 
Fig. 2. Cervical diseases are absent in K14E7/ERαN/− mice. (A) Mice of 
indicated genotypes were treated with E2 for 6 months. Representative 
images of hematoxylin and eosin-stained cervical sections are shown. White 
arrowhead indicates an invading carcinoma and arrows point to epithelia. 
Scale bar, 100 μm. (B) Cervical epithelial cell proliferation is greatly reduced 
in K14E7/ERαN/− mice. Cervical sections were stained for Ki67 (brown 
nuclei staining) and nuclei were counterstained with hematoxylin. Scale 
bar, 50 μm. (C) Results shown in B are quantified and displayed as mean ± 
standard error of the mean (n = 3), *P = 0.02. (D) ASM is absent in K14E7/
ERαN/− mice. Representative images of hematoxylin and eosin-stained 
cervical transformation zone are shown. White and black arrowheads point 
to squamous and columnar epithelium, respectively. Note that squamous 
epithelia are embedded in columnar epithelium in K14E7/ERα+/− mice but 
not in K14E7/ERαN/− mice. ASM incidence is indicated in the lower right 
corner of each image. Scale bar, 100 μm.
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(37). Overexpression of constitutively active β-catenin (downstream 
of Wnt signaling) augments cervical carcinogenesis in K14E7 mice 
(40).
Potential mechanisms by which the ERα DBD mutant inhibits  
cervical carcinogenesis
It was surprising that cervical disease did not arise in K14E7/ERαN/f 
mice because, in the absence of Cre activity, they possessed an allele 
that expresses wt ERα. It is intriguing to note that enhanced eosin 
staining (presumably representing collagens and other acidic extra-
cellular matrix proteins) in cervical stroma of K14E7/ERαN/f mice 
(Supplementary Figure S1, available at Carcinogenesis Online) was 
also observed in mice treated with fulvestrant or raloxifene (15). 
These selective ER modulators are efficient in treating cervical cancer 
in HPV transgenic mice (15). One possibility for the lack of cervi-
cal disease in K14E7/ERαN/f mice is that the mutant ERα predomi-
nantly forms heterodimer with wt ERα and thus inhibits its binding to 
EREs. Such a dominant-negative effect of the mutant, however, does 
not appear to be significantly at play because PR expression, which 
depends on ERα DBD function (Supplementary Figure S2, available 
at Carcinogenesis Online), was retained in the cervix of most K14E7/
ERαN/f mice (Figure  5B). In addition, the E207A/G208A mutant 
does not inhibit expression of an ERE-dependent reporter gene even 
when overexpressed 10 times more than wt ERα (18). Nonetheless, 
Fig. 3. ERα DBD mutant does not inhibit cervical epithelial cell proliferation when treated with E2 for short term. (A) Mice with indicated genotypes 
were treated with E2 for 4 weeks starting at 4–6 weeks of age and cervical sections were stained for BrdU. Nuclei were counterstained with hematoxylin. 
Representative images are shown. Red arrowheads point to suprabasal cells stained positive for BrdU. Black lines separate epithelium from stroma. Scale bar, 
25 μm. (B) Results shown in A are quantified and displayed as mean ± standard error of the mean (n = 3). *P = 0.02 compared with NGT/ERα+/f, **P = 0.02 
compared with NGT/ERαN/f.
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Fig. 5. E7 is expressed and the ERα classical pathway is active in K14E7/ERαN/f mice. (A) E7 is functional in K14E7/ERαN/f mice. Mice were treated with E2 
for 6 months and cervical tissue sections were stained for MCM7 (upper panel) or p16 (lower panel). Nuclei were counterstained with hematoxylin. Black lines 
separate epithelium and stroma. (B) The ERα classical pathway is active in K14E7/ERαN/f cervix. Cervical tissue sections prepared from mice shown in A were 
subjected to immunohistochemistry for ERα (upper panel) and PR (middle and lower panels). Nuclei were counterstained with hematoxylin. Number of mice with 
the shown staining pattern and total number of mice analyzed are indicated at the upper right corner. Black lines separate epithelium and stroma. Scale bar, 50 μm.
Fig. 4. ERα DBD mutant inhibits cervical epithelial cell proliferation when treated with E2 for long term. (A) Mice with indicated genotypes were treated with 
E2 for 6 months starting at 4–6 weeks of age and cervical sections were stained for BrdU. Nuclei were counterstained with hematoxylin. Representative images 
are shown. Red arrowheads point to suprabasal cells stained positive for BrdU. Black lines separate epithelium from stroma. Scale bar, 50 μm. (B) Results shown 
in A are quantified and displayed as mean ± standard error of the mean (n = 3), *P = 0.05. (C) Mice with indicated genotypes were treated with E2 for 4 weeks 
starting at 6–6.5 months of age. Cervical sections were stained for BrdU and nuclei were counterstained with hematoxylin. Representative images are shown. 
Black lines separate epithelium from stroma. Scale bar, 50 μm. (D) Results shown in C are quantified and displayed as mean ± standard error of the mean (n = 3). 
*P = 0.02 compared with NGT/ERα+/f, **P = 0.02 compared with NGT/ERαN/f.
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the fact that PR expression was absent in cervical epithelial cells of 
three K14E7/ERαN/f mice (Figure 5B) suggests that a dominant-nega-
tive effect may arise in some contexts. Another possibility is that the 
mutant ERα results in epigenetic changes in, at least, a subset of clas-
sical pathway target genes necessary for cancer promotion. We would 
argue that such an epigenetic effect becomes more pronounced over 
time because significant impact on cell proliferation was observed 
after 6-month E2 treatment but not after 4-week treatment in K14E7/
ERαN/f mice (Figure 4). The third possibility is that a balance between 
classical (i.e. ERE binding) and non-classical pathway (i.e. interac-
tion with other transcription factors such as AP1 and Sp1) is impor-
tant for cervical carcinogenesis. We favor this possibility because 
the mutant ERα (E207A/G208A) used in this study activates an AP1 
reporter gene and non-ERE target genes (18), and because microarray 
analyses have suggested that it augments non-classical activity com-
pared with wt ERα (41). Although a precise mechanism for inhibition 
of cervical carcinogenesis by the E207A/G208A mutant remains to be 
determined, the result further supports our conclusion that the classi-
cal pathway is necessary for cervical carcinogenesis.
A role of the classical pathway in ERα-dependent cancers
Our results are the first to show that ERα DBD is necessary for the 
earliest stage of cervical carcinogenesis, which we had shown previ-
ously to be ERα dependent in mice (16). A role of ERα in cancer is 
best characterized in breast cancer and selective ER modulator tamox-
ifen is most widely used for treatment of ERα-positive breast cancer 
(42). However, those cancers often develop tamoxifen resistance and 
tamoxifen promotes growth of those resistant tumors. Disulfide ben-
zamide, an ER zinc finger inhibitor, restores tamoxifen sensitivity in 
tamoxifen-resistant breast cancer models (31). Interestingly, it corre-
lates to inhibition of tamoxifen-induced ERα binding to EREs but not 
to non-EREs, suggesting that ERE binding (i.e. classical pathway) is 
crucial for tamoxifen-mediated proliferation of drug-resistant breast 
cancer cells. C4-12 cell line cloned from MCF7 breast cancer cells 
does not express ERα, yet overexpression of the receptor promotes 
proliferation upon estrogen treatment (30). Human ERα DBD mutant 
(E203A/G204A; this mutant is equivalent to mouse ERα E207A/
G208A expressed in NERKI mice) promotes proliferation of C4-12 
cells; however, their proliferation is more strongly promoted by wt 
ERα (30). Combined with our results, these observations support the 
idea that the classical pathway is crucial for growth of ERα-dependent 
cancers.
In summary, our results provide strong genetic evidence for the 
requirement of ERα DBD for initiation of cervical carcinogenesis. 
Our results also suggest that selective inhibition of the ERα classical 
pathway or preferential activation of non-classical pathway may be 
effective in treating cervical cancer.
Supplementary material
Supplementary Figures S1 and S2 and Table SI can be found at http://
carcin.oxfordjournals.org/
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